A study of IMR-687 for the treatment of sickle cell disease in adult patients
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2017
At a glance
- Drugs IMR 687 (Primary)
- Indications Sickle cell anaemia
- Focus Therapeutic Use
- Sponsors Imara Inc
- 14 Sep 2017 According to an Imara media release, the company plans to initiate this study by end of 2017.
- 23 May 2017 New trial record
- 15 May 2017 According to an Imara media release, the company plans to initiate this study later in 2017.